Sandoz Press Releases & News The latest news from Sandoz International. http://www.sandoz.com New episode of Sandoz TV available Sandoz has just launched its ninth episode of Sandoz TV. http://www.sandoz.com/media_center/news/2012/press_releases/2012_05_15_sandoz_tv_episode9.shtml Sandoz testimony at FDA hearing on biosimilars will emphasize need for consistent regulatory standards across all biologics Sandoz announced today that Dr. Mark McCamish, Head of Global Biopharmaceutical Development, will present on behalf of the Novartis Group of companies (Novartis) at the May 11 Food and Drug Administration (FDA) public hearing on draft guidances related to the development of biosimilar products. http://www.sandoz.com/media_center/news/2012/press_releases/2012_05_09_Sandoz_testimony_at_FDA.shtml Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company globally and in the US Definitive agreement to acquire Fougera Pharmaceuticals for USD 1.525 billion in an all-cash transaction http://www.sandoz.com/media_center/news/2012/press_releases/2012_05_02_Sandoz_acquire_Fougera.shtml Novartis announces Q1 2012 results Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges http://www.sandoz.com/media_center/news/2012/press_releases/2012_04_24_2012_4_24_novartis_q1_2012_results.shtml Available now! New episode of Sandoz TV Sandoz has just launched its eighth episode and third year of Sandoz TV. http://www.sandoz.com/media_center/news/2012/press_releases/2012_02_13_sandoztv_e8.shtml Novartis announces Q4/Full Year 2011 results Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011 http://www.sandoz.com/media_center/news/2012/press_releases/2012_01_25_novartis_q4_2011_results.shtml Sandoz initiates two more Phase III biosimilar trials, reinforcing long-term global leadership commitment Sandoz announced today that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen®) in the US market, the other for its global pegfilgrastim development program (Amgen's Neulasta®). http://www.sandoz.com/media_center/news/2012/press_releases/2012_01_19_biosimilars_phaseIII_trials.shtml Sandoz Head Jeff George Named Top "40 Under 40" Sandoz is pleased to announce that Jeff George, global Head of Sandoz, has been named part of Fortune Magazine’s 2011 Top “40 Under 40”. http://www.sandoz.com/media_center/news/2011/press_releases/2011_10_28_article.shtml New episode of Sandoz TV now available! Sandoz is pleased to announce that it has launched a new, seventh episode of Sandoz TV. http://www.sandoz.com/media_center/news/2011/press_releases/2011_10_27_article.shtml Novartis announces Q3 2011 results Novartis achieves strong third quarter financial performance and pipeline progress. http://www.sandoz.com/media_center/news/2011/press_releases/2011_10_25_novartis_q3_2011_results.shtml